Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

Abstract We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvo...

Celý popis

Podrobná bibliografia

Vydané v:	Open forum infectious diseases Ročník 8; číslo 2; s. ofab050
Hlavní autori:	Seftel, David, Boulware, David R
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	US Oxford University Press 01.02.2021
Predmet:	Brief Report Editor's Choice COVID-19 cohort coronavirus fluvoxamine SARS-COV-2
ISSN:	2328-8957, 2328-8957
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!